Innovation Pharmaceuticals Inc (IPIX)

[mdphd2008]

Dear fellow CTIX followers, today is certainly an exciting day and milestone for cellceutix and it's shareholders.

We have now really solidified prurisol, our third drug in clinical trials, as a potential blockbuster.

Moreover, with the news of orbactiv receiving expedited FDA approval, I am even more excited about the future of Brilacidin.

With brilacidin vs. orbactiv, we simply have a better mouse trap, and in due time I am confident that the market and scientific community will understand and respect that.

For those that appreciate a bit of logic: daptomycin is an improvement over vancomycin, Orbactiv is an improvement over vancomycin, and finally brilacidin is an improvement over daptomycin. Thus, daptomycin is an improvement over orbactiv, hence my comments of a better mouse trap.

As a clinician that works at a large trauma hospital in the northeast taking care of patients in a critical care setting, as well as my scientific background in neuro-immunology, I can attest that it so rare to see such promise from a small biotechnology company.

I have been following CTIX consistently over the past 3 years and with its past accomplishments in place, I have no doubt that the next 3 years will be even more exciting and revolutionary.